KRAS, a critical oncogenic driver of lung cancer, is frequently co-mutated in lung cancers: 27% of patients with KRAS mutations also have deleterious mutations in KEAP1/NFE2L2 genes, comprised of 24% KEAP1 and 3% NFE2L2 co-mutations [22]. Here, NFE2L2 is linked to lung cancer.